Category: Therapies, Treatments, and Procedures

Kellogg retina surgeons implant Argus II Retinal Prosthesis, or ‘bionic eye,’ for two patients with end-stage retinitis pigmentosa ANN ARBOR, Mich. — Retina surgeons at the University of Michigan Kellogg Eye Center have performed the first – and second – surgeries in the United States to implant an artificial retina, or “bionic eye,” since the U.S. Food and [Read More]

The principal difference between the two leading FDA-approved anti-VEGF drugs, Eylea and Lucentis for treatment of retinal hemorrhage has been accepted as the difference in length of time between injections. A new study, however, found no significant difference in injection scheduling between the drugs. The overall mean days between injections differed by only 1.8 days [Read More]

Early treatment with a new drug called JETREA® (formerly called ocriplasmin) has shown effectiveness in lessening the risk of macular pucker, macular hole, and vitreomacular traction (VMT). These conditions are caused by the tugging on the macula by the vitreous gel, which is attached to the retina at several points. As the vitreous shrinks with [Read More]

by Liz Trauernicht, Director MD Foundation A significant amount of evidence finds that very bright light, especially blue light, can damage the macula. Traditional slit lamp devices used during eye exams produce high light levels, which may be problematic for people with macular degeneration. Before these devices can be used effectively, the pupil of the [Read More]